Information  X 
Enter a valid email address

Physiomics PLC (PYC)

  Print      Mail a friend

Friday 09 February, 2018

Physiomics PLC

Contract Award

RNS Number : 3763E
Physiomics PLC
09 February 2018
 

Physiomics plc

("Physiomics") or ("the Company")

 

 

Contract award

 

Physiomics secures third major pharmaceutical client in matter of months

 

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is delighted to announce that it has been awarded a contract by a further major (global top-10) pharmaceutical client.  The project, which has a value of approximately £70k, is expected to be completed during the Company's current financial year and involves the use of Physiomics' Virtual Tumour technology in a pre-clinical setting.

 

Physiomics' Virtual Tumour is a sophisticated computer model that simulates tumour cell division and predicts the effect of different anti-cancer regimes to support pre-clinical and clinical oncology development programs. Virtual Tumour helps customers to balance efficacy and toxicity and to prioritise the most effective drug combinations while reducing time and cost.

 

Dr Jim Millen, CEO said: "We believe that the signing of agreements with three major pharmaceutical clients within the space of three months is a real sign of the confidence in our technology that is starting to build within the industry.  Our aim now will be to develop longer-term relationships with these major companies and to secure further pre-clinical and clinical projects."

 

Enquiries:

 

Physiomics plc                                                  

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

WH Ireland Limited (nomad)

Katy Mitchell

James Sinclair-Ford

+44 (0) 161 832 2174

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is a solutions provider to the R&D based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

 

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

 

Physiomics senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.

 

For more information please visit:

www.physiomics-plc.com

www.twitter.com/Physiomics

www.linkedin.com/company/physiomics-plc/


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTUGUWUPUPRGMR

a d v e r t i s e m e n t